Skip to content

MOBILion Methods Demonstrates Integration of SLIM Expertise with Orbitrap Expertise Yielding Sensitivity Features

Proof of Idea Introduced at HUPO Integrates SLIM Expertise with Thermo Scientific Orbitrap Exploris 480 Mass Spectrometer to Present Vital Sign Enhancement

CHADDS FORD, Pa., Jan 11, 2023 /PRNewswire/ — MOBILion Methods, Inc., a life science instruments and instrumentation firm, offered on the Human Proteome Group (HUPO) World Congress the primary of its variety proof of idea integrating their SLIM (constructions for lossless ion manipulation) expertise with the Thermo Scientific™ Orbitrap Exploris™ 480 mass spectrometer.

A mission involving MOBILion and ThermoFisher goals to handle the trade’s present limitations in sensitivity, together with challenges in detecting low abundance analytes. In a co-authored presentation on the HUPO 2022 World Congress in Cancun, Mexico Final month, the analysis groups demonstrated the usage of SLIM expertise to reinforce sign intensities on the Orbitrap Exploris 480 mass spectrometer system as much as 200x. This sign improve was proven for low abundance peptide alerts usually noticed in proteomic workflows. The power to reliably detect and establish peptides and proteins from single remoted cells represents the following frontier in proteomics that warrants an ultra-high sensitivity technological resolution. Additional particulars concerning this proof of idea might be seen right here.

MOBILion is proving its SLIM expertise is a platform expertise well-suited for personalisation, permitting it to be tuned to quite a lot of mass spectrometer platforms. On this most up-to-date iteration, MOBILion designed the SLIM prototype to separate ions into packets which are fed into the Orbitrap in a uniquely customizable method that solely the SLIM expertise can accomplish, growing the sensitivity to seize extra low abundance proteins and finally improve the variety of proteoforms characterised per experiment. In 2021, MOBILion launched its first SLIM-based industrial product, MOBIE®, a results of its partnership with Agilent Applied sciences. MOBIE® was designed to offer quick, environment friendly, extremely reproducible Excessive Decision Ion Mobility (HRIM) separations to separate and establish molecules that typical liquid chromatography both fails to separate, or require prohibitively lengthy separation workflows. The instrument accelerates and simplifies workflows for quite a lot of analyte lessons, together with peptides, proteins, lipids and glycans, with evaluation that’s 5 to 60 instances sooner and considerably extra reproducible than typical separation strategies.

“We’re excited in regards to the debut of this second iteration of SLIM expertise as one other demonstration of how we’re in a position to advance separation science. The early suggestions from KOLs following the proof of idea integration with the Orbitrap platform has been overwhelmingly constructive. We’re trying ahead to proceed to work with ThermoFisher to advance the idea even additional and enhance the efficiency of the Orbitrap platform of mass spectrometers,” says Dr. Melissa ShermanCEO of MOBILion Methods Inc.

To be taught extra about MOBILion Methods and its separations expertise, together with MOBIE®, go to

About MOBILion

MOBILion Methods Inc. is advancing separation science and unraveling complicated analyzes with the commercialization of merchandise based mostly on Constructions for Lossless Ion Manipulation (SLIM) platform expertise. MOBILion’s merchandise present deeper stage characterization than what is feasible with incumbent approaches, revealing what others go away unseen. When built-in with mass spectrometry, MOBILion’s separation expertise supplies larger decision, sooner and extra reproducible evaluation to disclose molecules most necessary in characterizing biologic therapeutics, discovering biomarkers, enhancing the accuracy of diagnostic checks, and guaranteeing meals and environmental security. Processing population-scale samples in weeks versus years and detecting molecules different devices miss, make remedies safer and more practical, speed up illness prediction and prognosis, and improve the event of recent therapies. The corporate is headquartered in Chadds Ford, Pennsylvania throughout the Philadelphia biopharmaceutical and medical innovation hall. Join with us on LinkedIn or go to



Leave a Reply

Your email address will not be published. Required fields are marked *